Evidence map›Paper›PMID 36599321›Full record

Trial reportCerebrovascular diseases (Basel, Switzerland)2023

Effect of Magnesium on Deterioration and Symptomatic Hemorrhagic Transformation in Cerebral Ischemia: An Ancillary Analysis of the FAST-MAG Trial.

Shawn Fan, Michael Jang, May Kim-Tenser, Kristina Shkirkova, David S Liebeskind, Sidney Starkman, Juan Pablo Villablanca, Scott Hamilton, Andrew Naidech, Jeffrey L Saver and 2 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cerebrovascular diseases (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Shawn FanDuke-NUS Medical School, Singapore, Singapore, sfan@wustl.edu.
Michael JangRoxanna Todd Hodges Stroke Program, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
May Kim-TenserRoxanna Todd Hodges Stroke Program, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Kristina ShkirkovaZilkha Neurogenetic Institute, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
David S LiebeskindDepartment of Neuroradiology, University of California Los Angeles Comprehensive Stroke Center, Los Angeles, California, USA.
Sidney StarkmanDepartment of Neuroradiology, University of California Los Angeles Comprehensive Stroke Center, Los Angeles, California, USA.
Juan Pablo VillablancaDepartment of Neuroradiology, University of California Los Angeles Comprehensive Stroke Center, Los Angeles, California, USA.
Scott HamiltonDepartment of Neurology, Stanford University School of Medicine, Stanford, California, USA.
Andrew NaidechDepartment of Neurology, Northwestern University Feinberg School of Medicine, Evanston, Illinois, USA.
Jeffrey L SaverDepartment of Neuroradiology, University of California Los Angeles Comprehensive Stroke Center, Los Angeles, California, USA.
Nerses SanossianRoxanna Todd Hodges Stroke Program, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
FAST-MAG Investigators and Coordinators
University of California, Los Angeles · USUniversity of Southern California · USDuke-NUS Medical School · SGNorthwestern University · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMagnesium (Mg) is a neuroprotectant in preclinical models. Lower serum Mg levels have been associated with symptomatic hemorrhagic transformation (HT) in patients with ischemic stroke. Early treatment of acute ischemic stroke with Mg may reduce rates of symptomatic HT.

methodsIn this post hoc study of the Field Administration of Stroke Therapy Magnesium (FAST-MAG) trial, 1,245 participants with a diagnosis of cerebral ischemia received 20 g of Mg or placebo initiated in the prehospital setting. Posttreatment serum Mg level was measured for 809 participants. Cases of clinical deterioration, defined as worsening by ≥4 points on the National Institute of Health Stroke Scale (NIHSS), were imaged and evaluated for etiology. Symptomatic HT was defined as deterioration with imaging showing new hemorrhage.

resultsClinical deterioration occurred in 187 and symptomatic HT in 46 of 1,245 cases of cerebral ischemia. Rates of deterioration and symptomatic HT were not significantly lower in those who received Mg (15.7% vs. 14.4%, p = 0.591; 2.8% vs. 4.6%, p = 0.281). In cases where serum Mg level was obtained posttreatment, lower serum Mg level (<1.7 mg/dL) was associated with significantly higher rates of deterioration and symptomatic HT (27.5% vs. 15.5%, p = 0.0261; 11.6% vs. 3.65%, p = 0.00819).

conclusionsTreatment with Mg did not significantly reduce rates of clinical deterioration or symptomatic HT. Future analysis should address whether treatment with Mg could have influenced the subgroup with low serum Mg at baseline.

Indexed as

Brain IschemiaClinical DeteriorationIschemic StrokeStrokeCerebral HemorrhageCerebral InfarctionHumansMagnesiumMagnesiumCerebral ischemiaHemorrhagic transformationMagnesium

Identifiers

PMID36599321
PMCPMC10627486
OpenAlexW4313546050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.